A Mixed AdComm: REMS Seems Possible For GSK’s Anemia Drug, Dual Indication Likely Needs More Data

GSK building
GSK’s Daprodustat Went 1 for 2 At Its 26 October US FDA Advisory Committee Meeting • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers